Industry Briefs: July 30, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.
Company News
Coldstream Laboratories is expanding its Louisville, Kentucky, sterile-manufacturing facility. Read More
Dendreon has announced a restructuring plan to reduce costs by approximately $150 million annually. The plan includes the closure of its Morris Plains, New Jersey, manufacturing facility. Read More
GlaxoSmithKline has announced the acquisition of 79% of Human Genome Sciences’s shares, and is beginning a subsequent offering period to acquire the remaining shares. Read More
NSF International has acquired Becker & Associates Consulting, a clinical, regulatory, and scientific-consulting firm. Read More
People Notes
Array BioPharma has named Andrew Robbins as senior vice-president of commercial operations. Read More
Daicel has appointed Dieter Heckmann as executive officer. He will assume responsibility for global operations of the Chiral Pharmaceutical Ingredients company, reporting to Misao Fudaba, president and CEO of Daicel.
Quanticate has appointed Sally Du Toit as vice-president of pharmacovigilance and Chris Cramer as vice-president of clinical data management. Read More
Takeda Pharmaceutical has appointed Christopher Hohman as vice-president of its corporate communications department. Read More
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
